Minute Insight: Pear Therapeutics Files For Bankruptcy, Hopes To Find Buyer For PDT Assets
Executive Summary
A few weeks after announcing that it was exploring its "strategic options," Pear Therapeutics announced that it is filing for bankruptcy and is not filling new prescriptions for its digital therapeutics.
You may also be interested in...
Minute Insight: New Butterfly Network CEO Has Tough Job Ahead
The handheld ultrasound company made a loss last quarter, but secured FDA authorization for a new ultrasound software and named new leadership.
Finance Watch: Lucky Few Raise Cash While Many Public Biotechs Cut Costs
Public Company Edition: ImmunoGen received the first $75m under a $175m term loan, while Protagonist raised $100m in a follow-on offering, but companies with bankruptcy filings and job cuts outpaced those accessing new capital by a wide margin in late March and early April.
Is Time Nearly Up For Pear? The PDT Company Could Be Bargain For Acquirer
Despite earlier efforts to restructure, the company is still struggling to meet its revenue targets, and issued a statement suggesting that further measures, including liquidation, may be necessary.